Use of Home Device for Early Detection of Neovascular Age-Related Macular DegenerationLoewenstein A.
Department of Ophthalmology, Tel Aviv Medical Center, Sidney A. Fox Chair in Ophthalmology, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Early treatment for choroidal neovascularization (CNV) is an important part of preserving visual function for patients with age-related macular degeneration. Preferential hyperacuity perimetry (PHP) provides high accuracy, sensitivity and specificity for detecting changes in lesions in diagnostic and treatment stages. The ForeseeHome is a PHP device designed for home use by patients. Regular use alerts retina specialists and patients of detected changes and allows patients to come in for visits when CNV begins or recurs. To maximize the benefit of recent breakthroughs in CNV treatment, patients should be better monitored with the ForeseeHome to detect new CNV while their vision is still good, and to promptly manage recurrence after treatment.
© 2012 S. Karger AG, Basel
- Olsen TW, Feng X, Kasper TJ, et al: Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004;111:250–255.
- Vander JF, Morgan CM, Schatz H: Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology 1989;96:1422–1426.
- Boyer DS, Antoszyk AN, Awh CC, et al: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246–252.
- Kaiser PK, Brown DM, Zhang K, et al: Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthamol 2007;144:850–857.
Rauch R, Weingessel B, Maca SM, et al: Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 2011, E-pub ahead of print.
- Javitt JC, Zhou Z, Maguire MC, et al: Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003;110:1534–1539.
- Querques G, Querques L, Rafaeli O, et al: Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci 2011;52:7012–7018.
- Lai Y, Grattan J, Shi Y, et al: Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimetry. Retina 2011;31:1620–1626.
- Querques G, Berboucha E, Leveziel N, et al: Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthalmol 2011;95:986–991.
- Loewenstein A, Ferencz JR, Lang Y, et al: Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina 2010;30:1058–1064.
- Stur M, Manor Y: Long-term monitoring of age-related macular degeneration with preferential hyperacuity perimetry. Ophthalmic Surg Lasers Imaging 2010;41:598–606.
- Das R, Shi Y, Silvestri G, et al: Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina 2009;29:1013–1018.
Isaac DL, Avila MP, Cialdini AP: Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. Arq Bras Oftalmol 2007;70:771–776.
Loewenstein A, Richard & Hinda Rosenthal Foundation: The significance of early detection of AMD: Richard & Hinda Rosenthal Foundation lecture, The Macula Society 29th annual meeting. Retina 2007;27:873–878.
- Kampmeier J, Zorn MM, Lang GK, et al: Comparison of preferential hyperacuity perimeter test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration (in German). Klin Monbl Augenheilkd 2006;223:752–756.
- Alster Y, Bressler NM, Bressler SB, et al: Preferential hyperacuity perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology 2005;112:1758–1765.
- Goldstein M, Loewenstein A, Barak A, et al: Results of a multicenter clinical trial to evaluate the peripheral hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005;25:296–303.
- Loewenstein A, Malach R, Goldstein M, et al: Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003;110:966–970.
- CATT Research Group: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
Heier JS: VEGF Trap-Eye Phase III Trial Results. VIEW 1 results. Angiogenesis, Exudation, and Degeneration 2011, Miami, February 2011.
Schmidt-Erfurth U: VEGF Trap-Eye Phase III Trial Results. VIEW 2 results. Angiogenesis, Exudation, and Degeneration 2011, Miami, February 2011.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.